Shopping Cart
- Remove All
- Your shopping cart is currently empty
Ezabenlimab (BI-754091) is a humanized monoclonal antibody targeting programmed cell death protein-1 with antitumor activity that blocks the interaction of PD-1 with PD-L1 and PD-L2, inhibits tumor growth in vivo, and can be used to study advanced solid tumors.
Pack Size | Price | Availability | Quantity |
---|---|---|---|
1 mg | $197 | In Stock | |
5 mg | $516 | In Stock | |
10 mg | $828 | In Stock | |
25 mg | $1,230 | In Stock | |
50 mg | $1,650 | In Stock |
Description | Ezabenlimab (BI-754091) is a humanized monoclonal antibody targeting programmed cell death protein-1 with antitumor activity that blocks the interaction of PD-1 with PD-L1 and PD-L2, inhibits tumor growth in vivo, and can be used to study advanced solid tumors. |
Targets&IC50 | IFN-γ:0.9 nM (EC50), PD-1/PD-L1 (cynomolgus Monkeys):5.61 nM (IC90), PD-1/PD-L2 (cynomolgus Monkeys):7.54 nM (IC90), PD-1/PD-L1 (CHO cells):4.14 nM (IC90), PD-1/PD-L2 (CHO cells):3.98 nM (IC90) |
In vitro | Ezabenlimab inhibited the interaction of PD-1 with PD-L1 and PD-L2 in CHO cells with IC90 of 4.14 nM and 3.98 nM, respectively; it also inhibited the interaction of PD-1 with PD-L1 and PD-L2 in cynomolgus Monkeys with IC90 of 5.61 nM and 7.54 nM, respectively. In addition, Ezabenlimab was able to increase IFN-γ secretion in CD3-positive T cells after primary human antigen stimulation, with an EC50 of 0.9 nM. In combination with BI 754111, 200 nM Ezabenlimab enhanced IFN-γ secretion. [1] |
In vivo | In the hPD-1 knock-in mouse model, intraperitoneal injection of 0.3-30 mg/kg Ezabenlimab, single or twice a week or every 3 weeks, inhibited tumor progression and demonstrated significant antitumor activity. [1] |
Alias | BI-754091, BI754091 |
Cas No. | 2249882-54-8 |
Storage | store at low temperature | store at -20°C | Shipping with blue ice. |
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.